MAPT and Alzheimer disease: The GSK-3 hypothesis of Alzheimer’s Disease, postulated by Hooper et al. in 2008, states that GSK-3 over-activity is involved in the amyloid cascade of AD, being responsible for an increased Aβ production and tau hyper-phosphorylation.